RAFAEL MIRABAL: Open Payments
NPI 1134755663 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$950 in 40 payments from 13 companies in 2025. Trend: 2023 $1,029 · 2024 $1,106 · 2025 $950
Food & beverage: $950
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $237 |
| GlaxoSmithKline, LLC. | 7 | $168 |
| Sumitomo Pharma America, Inc. | 9 | $150 |
| Novo Nordisk Inc | 6 | $129 |
| Lilly USA, LLC | 3 | $64 |
| PFIZER INC. | 2 | $41 |
| Averitas Pharma Inc. | 1 | $31 |
| Exact Sciences Corporation | 1 | $28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
| Amgen Inc. | 1 | $21 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, GEMTESA, Ozempic, Rybelsus, JARDIANCE, MOUNJARO, BREZTRI.
Industry payments across FL — which companies pay providers there.
